Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480387 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection
A Phase 2 study of Treatment of Hepatitis C, sponsored by Peter J. Ruane, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT02480387: Completed Phase 2 study of Treatment of Hepatitis C, sponsored by Peter J. Ruane, M.D..
NCT02480387 is a Phase 2 study of Treatment of Hepatitis C that has completed, run by Peter J. Ruane, M.D.. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02480387, a Phase 2 study of Treatment of Hepatitis C, has completed, sponsored by Peter J. Ruane, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA \< 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- Treatment: treatment
Conditions Studied
Interventions
- DRUG Ledipasvir/Sofosbuvir FDC
Study Locations (1)
California
- Peter J. Ruane, MD, Inc. - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT02480387 record still lists
NCT02480387 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Treatment of Hepatitis C appearing as the primary indexed condition, and to 1 intervention - of which Ledipasvir/Sofosbuvir FDC is the first listed.
NCT02480387 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02480387 about?
NCT02480387 is a clinical study titled "Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection". Target Population: Hepatitis C Treatment Naïve, non-cirrhotic, Chronic genotype 1 hepatitis C virus (HCV) infected adults that are co-infected with human immunodeficiency virus (HIV)-1and have HCV RNA \< 6 x106 IU/mL Duration of Subjects will be treated for 8 weeks and followed for 24 weeks post- T...
What is the current status of trial NCT02480387?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2015-05. Estimated completion is 2016-01.
What conditions does trial NCT02480387 study?
This clinical trial studies the following conditions: Treatment of Hepatitis C.
What interventions are being tested in trial NCT02480387?
The interventions under investigation include: Ledipasvir/Sofosbuvir FDC (DRUG).
Who is sponsoring clinical trial NCT02480387?
This trial is sponsored by Peter J. Ruane, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02480387 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02480387's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia